Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Z. Sarah, B. Sansom, E. H. Baker (London, United Kingdom). Lack of therapeutic potential for topical metformin in treatment of airway secretion dehydration in cystic fibrosis. Eur Respir J 2009; 34: Suppl. 53, 463

Member's Comments

No comment yet.

Related content which might interest you: Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis Source: Eur Respir J 2002; 19: 294-302 Year: 2002 Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016 Year: 2017 RhDNase after airway clearance therapy improves peripheral airway patency in children with cystic fibrosis Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs Year: 2006 Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells Source: Eur Respir J 2015; 45: 428-439 Year: 2015 The effect of inhaled steroids on bronchial hyperreactivity, oxidative status, clinical and inflammatory paramerters in patients with cystic fibrosis Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007 Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration Source: Eur Respir J, 59 (2) 2100185; 10.1183/13993003.00185-2021 Year: 2022 An anti-inflammatory effect of azithromycin in cystic fibrosis Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010 Recommended shielding against SARS-CoV-2 impacts physical activity levels and adherence to airway clearance therapy in patients with cystic fibrosis Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 Pharmacological treatment of the biochemical defect in cystic fibrosis airways Source: Eur Respir J 2001; 17: 1314-1321 Year: 2001 Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017 Year: 2018 Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies Source: Eur Respir J 2017; 49(1): 1600903; DOI: 10.1183/13993003.00903-2016 Year: 2017 Use of a new feedback tool to optimize inhaled aerosol therapy in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 261s Year: 2006 Role of CF ion transport defect in airway inflammation and implication for antiinflammatory therapies Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease Year: 2012 GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003 Inhaled mannitol as treatment for children with cystic fibrosis Source: Annual Congress 2008 - The use of inhaled mannitol for assessing airway disease Year: 2008 Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice Source: Eur Respir J 2011; 37: 72-78 Year: 2011